Marcio Souza
About Marcio Souza
Marcio Souza is the President & CEO of PTC Therapeutics, with a background in pharmacy and business, and experience across several biopharmaceutical companies.
Marcio Souza: President & Chief Executive Officer
Marcio Souza currently serves as the President and Chief Executive Officer. His leadership role encompasses strategic planning, business development, and overseeing the company's operations. Marcio has accumulated extensive experience in executive management, particularly within the biotechnology and pharmaceutical sectors.
Executive Roles at PTC Therapeutics
Marcio served as Chief Operating Officer at PTC Therapeutics from May 2017 to April 2020. During this period, he was responsible for the company's operational strategies and overseeing various departments. Prior to this, he was the Senior Vice President and Head of Product Strategy from July 2016 to May 2017, where he played a crucial role in guiding product development and market positioning.
Previous Positions in Biotech and Pharma
Marcio Souza has a rich history in the biotech and pharmaceutical industries. He has held key positions at NPS Pharmaceuticals, Shire Human Genetic Therapies, and Sanofi Genzyme Corporation. These roles have allowed him to develop a strong background in pharmaceutical development, commercialization, and strategic planning.
Board Memberships
Marcio has been a board member of Aeglea BioTherapeutics since June 2021. He also served on the board of directors of Clearpoint Neuro (formerly MRI Interventions) from May 2019 to May 2020. These roles underline his expertise and valued perspective in the governance and strategic direction of biotechnology companies.
Marcio Souza's Educational Background
Marcio earned a degree in pharmacy and biochemistry with a specialization in toxicology and clinical analysis from the University of São Paulo. He also holds an MBA from Fundação Dom Cabral. His academic background provides a strong foundation in both scientific and business disciplines, contributing to his effectiveness as an executive in the biotechnology industry.